info@hytanpeptides.com
Hytan Peptides — Peptide CDMORequest Project Quote
Technical guide

Peptide CDMO Quality Agreement: Who Owns Each Decision?

Two technical colleagues reviewing a blank responsibility grid and peptide sample at a meeting table; conceptual image

A peptide CDMO quality agreement should tell both parties who approves the specification, controls changes, reviews test data, releases a batch and responds when something goes wrong. A quotation can define price and delivery. The agreement defines how technical and quality decisions will be made.

Begin with product classification and project scope

Record the material’s intended use, destination market and contracted work before reusing a template. A cosmetic ingredient programme, a research material order and a pharmaceutical API programme can involve different legal duties. The words OEM, ODM, CRO and CDMO describe commercial arrangements; they do not determine regulatory classification.

For EU medicinal products, EMA’s GMP guidance on outsourced activities explains that relevant activities and responsibilities must be defined in written contracts. For an EU cosmetic, Regulation (EC) No 1223/2009 assigns specific duties to the responsible person, including a safety assessment and product information file. Those requirements should not be casually swapped between project types.

Put the handoffs in writing

  • Specification: who drafts, approves and revises material identity, tests and acceptance criteria?
  • Materials and subcontracting: which party qualifies suppliers and approves any outsourced testing or packaging?
  • Samples and methods: who provides reference information, reviews methods and resolves a result outside the agreed criteria?
  • Changes and deviations: who is notified, by when, and who decides whether work can continue?
  • Release and distribution: who approves the batch and which records accompany shipment?
  • Complaints and records: who investigates, retains evidence and coordinates a response?

Write the name of the responsible organisation against each action. If a third party performs a step, describe how information returns to the contracting parties. “Supplier handles quality” is too broad to guide an actual deviation.

Check the agreement against a real scenario

A packaging change before dispatch

Suppose the proposed closure changes after analytical work is complete. The agreement should show who raises the change, who assesses possible effects on the approved presentation and documentation, who authorises the revised package, and whether release or shipping is paused. If those owners cannot be found quickly, the agreement needs another pass.

Match the contract to the evidence package

List the documents expected at each stage: approved specification, agreed methods, batch COA, packaging records, shipment documents and any other project-specific items. A promise to supply “full documentation” is hard to verify without named deliverables.

Use our CDMO process overview to locate the decision points, then include intended use and requested responsibility split in the RFQ. The quality page explains which documents are reviewed by project and batch.

FAQ

Is a commercial purchase contract enough?

It may cover price and delivery, but technical responsibilities should be explicit. A separate quality agreement or suitable controlled section of the contract can provide that detail.

Does a supplier certificate replace a quality agreement?

No. A certificate describes a system or scope at a point in time. It does not allocate approval, release, deviation or record responsibilities for a particular project.

Who owns finished cosmetic safety in the EU?

EU Cosmetics Regulation (EC) No 1223/2009 assigns the responsible person duties for safety assessment and the product information file. A CDMO may supply evidence under contract, but the regulatory role must be identified for the finished product.

Primary references

← More guides